Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How many protein pairs can we chemically target?

Drug discovery today·2026
Same author

ChemBang: Expanding the Chemical Space Around Small Molecules.

Molecular informatics·2026
Same author

SAFR: Enabling Fragment-Based Drug Discovery with a Synthetic Binding Pose Data Set.

Journal of chemical information and modeling·2026
Same author

Dissecting Polypharmacology in Phenotypic Screening to Resolve Ferroptotic and Necrotic Cell-Death Mechanisms.

ACS medicinal chemistry letters·2026
Same author

Sexual Dysfunctions Associated with Proton Pump Inhibitors: Insights from VigiBase, the World Health Organization Pharmacovigilance Database.

Drug safety·2025
Same author

Enhancing molecular property prediction through data integration and consistency assessment.

Journal of cheminformatics·2025
Same journal

Structural pharmacology of TRPA1 channel.

Trends in pharmacological sciences·2026
Same journal

Recent advances in venom pharmacology reshaping venom-to-drug discovery.

Trends in pharmacological sciences·2026
Same journal

Engineering cells for solid tumor therapy.

Trends in pharmacological sciences·2026
Same journal

Targeting developmental reprogramming: hPSC insights for cancer interception.

Trends in pharmacological sciences·2026
Same journal

July 2026 issue first authors.

Trends in pharmacological sciences·2026
Same journal

Chronobiomaterials for circadian-aligned brain therapeutics.

Trends in pharmacological sciences·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library
10:17

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library

Published on: January 14, 2020

Conciliating binding efficiency and polypharmacology.

Jordi Mestres1, Elisabet Gregori-Puigjané

  • 1Chemogenomics Laboratory, Research Unit on Biomedical Informatics (GRIB), Institut Municipal d'Investigació Mèdica, Parc de Recerca Biomèdica, 08003 Barcelona, Catalonia, Spain. jmestres@imim.es

Trends in Pharmacological Sciences
|September 1, 2009
PubMed
Summary
This summary is machine-generated.

Binding efficiency is a key metric for drug lead selection. This study revises its definition to account for polypharmacology, proposing statistical standardization for improved drug design and therapeutic efficacy.

More Related Videos

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Related Experiment Videos

Last Updated: Jun 20, 2026

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library
10:17

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library

Published on: January 14, 2020

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Area of Science:

  • Medicinal Chemistry
  • Drug Discovery
  • Pharmacology

Background:

  • The association between molecular size and failure risk has led to the use of binding efficiency in lead selection.
  • The original concept of binding efficiency was limited to single-target ligand comparisons.
  • Current drug design trends involve targeting multiple receptors, necessitating a re-evaluation of binding efficiency.

Purpose of the Study:

  • To revise the definition of binding efficiency for modern drug design involving polypharmacology.
  • To analyze the impact of polypharmacology on binding efficiency using antipsychotic drugs.
  • To propose a method for standardizing binding efficiencies to reconcile them with polypharmacology.

Main Methods:

  • Retrospective analysis of antipsychotic drugs to examine binding efficiency dependency on polypharmacology.
  • Statistical standardization of target binding efficiencies against a large dataset of medicinal chemistry compounds.
  • Discussion on the interplay between binding efficiency and therapeutic efficacy for various drug discovery starting points.

Main Results:

  • Binding efficiency is significantly influenced by polypharmacology.
  • A proposed statistical standardization method can reconcile binding efficiency with polypharmacology.
  • The revised concept aids in optimizing natural products, random hits, and fragments for therapeutic efficacy.

Conclusions:

  • The traditional definition of binding efficiency requires revision to accommodate polypharmacology in drug discovery.
  • Statistical standardization offers a viable approach to adapt binding efficiency for multi-target drug design.
  • Optimizing binding efficiency in the context of polypharmacology is crucial for enhancing therapeutic efficacy.